EVARREST™ Fibrin Sealant Patch Post-Market Study

Inclusion Criteria: * Subjects ≥18 years of age, requiring an elective or urgent, open intra-abdominal, retroperitoneal, pelvic or non-cardiac thoracic surgical procedures; * Subjects or legally authorized representative must be willing to participate in the study and provide written informed consent. * Presence of an appropriate Target Bleeding Site as identified intra-operatively by the surgeon; Exclusion Criteria: * Subjects with known intolerance to blood products or to one of the components of EVARREST™ or unwilling to receive blood products; * Female subjects who are pregnant or nursing. * TBS is from a large defect in an artery or vein where the injured vascular wall requires repair and maintenance of vessel patency or where there would be persistent exposure of EVARREST™ to blood flow and/or pressure during absorption of the product; * TBS with major arterial bleeding requiring suture or mechanical ligation; * TBS within a contaminated or infected area of the body; * Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine; * Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure;